Computational Chemistry Intern

Genesis Molecular AI is bringing together a world‑class computational team to build out the industry's fastest and most accurate small molecule property predictions, by combining the power of machine learning and physics‑based methods. We are seeking early career scientists skilled in developing and applying computational chemistry and physics methodologies to help drive forward our challenging drug discovery programs.

• Develop and refine advanced computational chemistry and physics methodologies to help solve pressing challenges in our internal drug discovery programs
• Collaborate with our machine‑learning team on hybrid physics/ML methods for predicting structure, potency, and other properties relevant to drug discovery.
• Work closely with our computer‑aided drug discovery scientists and medicinal chemists to develop, benchmark, and deploy improvements to our drug discovery platform as it is applied to our internal and partnered drug discovery programs.

• A graduate student with a proven track record of applying or developing computational chemistry and physics methods.
• Passionate about building methods to solve real problems.
• A skilled programmer, preferably in Python, such that you can quickly implement your research ideas and analyze their performance.

• The opportunity to work on challenging, high‑impact computational chemistry research that is immediately deployed to accelerate the discovery of new medicines.
• A world‑class, tight‑knit team of good‑hearted people across software, machine‑learning, computational chemistry, medicinal chemistry, and biology.
• Competitive salary and equity. Medical, dental, and vision insurance, and a 401(k) program.
• One‑on‑one mentor to help guide your research and act as a point person for questions.

• Final date to receive applications:
  January 9, 2026
• Resume Review:
  Beginning January 12, 2026
• Interviews Kick‑Off:
  January 26, 2026
• Target
  
  Start Date:
  
  May–June 2026

Genesis Molecular AI is pioneering foundation models for molecular AI to unlock a new era of drug design and development. The company’s generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry‑leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. Genesis has raised over $300 million from leading AI, tech and life science‑focused investors, signed multiple AI‑focused research collaborations with major pharma partners, and is deploying GEMS to advance an internal therapeutics pipeline for a variety of high‑impact targets.

Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.